Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Di...(th Stanford Vermillion completed a 540-p...)

Date:3/3/2008

th Stanford, Vermillion completed a 540-patient clinical study evaluating the ability of the biomarker panel to classify individuals into high and low risk groups for PAD. These results will be published in a peer-reviewed clinical journal in the coming months. Additionally, Vermillion is establishing a clinical steering committee to guide and provide advice on a clinical trial to support registration of the PAD test with the U.S. Food and Drug Administration. Dr. Cooke will serve as a key member of this group.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward- looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermill
'/>"/>

SOURCE Vermillion, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Vermillion Receives NASDAQ Notice of Non-Compliance
2. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
3. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
4. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
5. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
6. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
7. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
8. Stanford researchers hear the sound of quantum drums
9. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
10. Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection
11. Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy